SEC Form 4 · accession 0001899977-26-000008
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark C. Schneyer
Officer — EVP, CHIEF FINANCIAL OFFICER
Period of report
Aug 5, 2026
Accepted (ET)
Aug 7, 2026 · 6:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001070494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 5, 2026 | M | 5,849 | $17.84 | A | 73,677 | D | |
| Common StockF3 | Aug 5, 2026 | S | 5,849 | $29.0029 | D | 67,828 | D | |
| Common Stock | Aug 6, 2026 | M | 14,292 | $17.84 | A | 82,120 | D | |
| Common Stock | Aug 6, 2026 | S | 5,000 | $29.00 | D | 77,120 | D | |
| Common Stock | Aug 6, 2026 | S | 9,292 | $29.3375 | D | 67,828 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $17.84 | Aug 5, 2026 | M | 5,849 | D | — | Mar 24, 2034 | Common Stock | 5,849 | 74,715 | D |
| Stock Option (Right to Buy)F4 | $17.84 | Aug 6, 2026 | M | 14,292 | D | — | Mar 24, 2034 | Common Stock | 14,292 | 60,423 | D |
Explanation of responses
- F1Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan.
- F2Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F425% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.